# US 2001/0024830 A1 · Methods for the selective regulation of DNA and RNA transcription and translation by photoactivation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024830 A1
- Document ID: US20010024830A1
- Status: Published application
- Kind: A1
- Application number: 09/837,830
- Filed: 2001-04-18
- Published: 2001-09-27
- Earliest claimed: 1997-02-20
- Assignees: Vanderbilt University
- Inventors: Frederick R. Haselton III; J. Steven Alexander
- Web page: https://patentgrep.com/patent/US20010024830A1

## CPC

- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides an isolated nucleic acid covalently linked to a photolabile caging group which reversibly prevents expression of the nucleic acid. The present invention further provides a method of selectively expressing a nucleic acid in a cell, comprising: a) covalently linking the nucleic acid to a photolabile caging group which reversibly prevents expression of the nucleic acid; b) introducing the nucleic acid of step (a) into the cell; and c) exposing the cell of step (b) to light, whereby exposure to the light unlinks the nucleic acid and the caging group and the nucleic acid is selectively expressed in the cell. Additionally provided is a method of selectively regulating the expression of an endogenous nucleic acid comprising: a) covalently linking a nucleic acid encoding an antisense nucleic acid to a photolabile caging group which reversibly prevents expression of the nucleic acid; b) introducing the nucleic acid of step (a) into the cell; and c) exposing the cell of step (b) to light, whereby exposure to the light unlinks the nucleic acid and the caging group and the nucleic acid is selectively expressed in the cell as an antisense nucleic acid which can bind to and inactivate a complementary nucleic acid within the cell.

## Claims

### Claim 1

An isolated nucleic acid covalently linked to a photolabile caging group which reversibly prevents expression of the nucleic acid.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the caging group is selected from the group consisting of DMNPE 1-(4,5-dimethyoxy-2-nitrophenyl) ethyl, (2-nitrophenyl) ethyl, 5-carboxymethoxy-2-nitrobenzyl, 5-carboxymethoxy-2-nitrobenzyl)oxy)carbonyl, 4,5-dimethyoxy-2-nitrobenzyl, 4,5-dimethoxy-2-nitrobenzyl)oxy)carbonyl, alpha-carboxy-2-nitrobenzyl, 1-(2-nitropheny)ethyl, 2-nitrobenzyl and Desoxybenzoinyl.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the caging group is DMNPE 1-(4,5-dimethyoxy-2-nitrophenyl) ethyl.

### Claim 4 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 5 (depends on 4)

A cell comprising the vector of claim 4.

### Claim 6 (depends on 1)

The nucleic acid of claim 1 in a pharmaceutically acceptable carrier.

### Claim 7 (depends on 4)

The vector of claim 4 in a pharmaceutically acceptable carrier.

### Claim 8

A method of selectively expressing a nucleic acid in a cell, comprising:
a) covalently linking the nucleic acid to a photolabile caging group which reversibly prevents expression of the nucleic acid;
b) introducing the nucleic acid of step (a) into the cell; and
c) exposing the cell of step (b) to light, whereby exposure to the light unlinks the nucleic acid and the caging group and the nucleic acid is selectively expressed in the cell.

### Claim 9 (depends on 8)

The method of claim 8, wherein the caging group is selected from the group consisting of DMNPE 1-(4,5-dimethyoxy-2-nitrophenyl) ethyl, (2-nitrophenyl) ethyl, 5-carboxymethoxy-2-nitrobenzyl, 5-carboxymethoxy-2-nitrobenzyl)oxy)carbonyl, 4,5dimethyoxy-2-nitrobenzyl, 4,5-dimethoxy-2-nitrobenzyl)oxy)carbonyl, alpha-carboxy2-nitrobenzyl, 1-(2-nitropheny)ethyl, 2-nitrobenzyl and Desoxybenzoinyl.

### Claim 10 (depends on 8)

The method of claim 8, wherein the caging group is DMNPE 1-(4,5dimethyoxy-2-nitrophenyl) ethyl.

### Claim 11 (depends on 8)

The method of claim 8, wherein the wavelength of the light is in a range from 300 nm to 400 nm.

### Claim 12 (depends on 8)

The method of claim 8, wherein the wavelength of the light is 365 nm.

### Claim 13 (depends on 8)

The method of claim 8, wherein the source of the light is a fiber optic device.

### Claim 14 (depends on 8)

The method of claim 8, wherein the source of the light is a laser.

### Claim 15 (depends on 8)

The method of claim 8, wherein the cell is selected from the group consisting of endothelial cells, epithelial cells and blood cells.

### Claim 16 (depends on 8)

The method of claim 8, wherein the cell is selected from the group consisting of lung cells, skin cells, eye cells and lymphocytes.

### Claim 17 (depends on 8)

The method of claim 8, wherein the nucleic acid is administered to the cell in a vector.

### Claim 18 (depends on 8)

The method of claim 8, wherein the nucleic acid is administered to the cell in a virus.

### Claim 19 (depends on 8)

The method of claim 8, wherein the nucleic acid is administered to the cell in a liposome.

### Claim 20 (depends on 8)

The method of claim 8, wherein the cell is in a subject.

### Claim 21 (depends on 8)

The method of claim 8, wherein the nucleic acid is in a pharmaceutically acceptable carrier.

### Claim 22 (depends on 17)

The method of claim 17, wherein the vector is in a pharmaceutically acceptable carrier.

### Claim 23 (depends on 18)

The method of claim 18, wherein the virus is in a pharmaceutically acceptable carrier.

### Claim 24 (depends on 19)

The method of claim 19, wherein the liposome is in a pharmaceutically acceptable carrier.

### Claim 25 (depends on 20)

The method of claim 20, wherein the subject is a human.

### Claim 26 (depends on 8)

The method of claim 8, wherein the nucleic acid comprises a gene selected from the group consisting of genes encoding gene products that promote cell killing, genes encoding proteins that are involved in inherited disorders, genes encoding gene products that promote wound repair, genes encoding gene products which promote cell-cell adhesion and genes encoding gene products which modulate cellular signals.

### Claim 27

A method of selectively regulating the expression of an endogenous nucleic acid comprising: a) covalently linking a nucleic acid encoding an antisense nucleic acid to a photolabile caging group which reversibly prevents expression of the nucleic acid; b) introducing the nucleic acid of step (a) into the cell; and c) exposing the cell of step (b) to light, whereby exposure to the light unlinks the nucleic acid and the caging group and the nucleic acid is selectively expressed in the cell as an antisense nucleic acid which can bind to and inactivate a complementary nucleic acid within the cell.

### Claim 28 (depends on 27)

The method of claim 27, wherein the caging group is selected from the group consisting of DMNPE 1-(4,5-dimethyoxy-2-nitrophenyl) ethyl, (2-nitrophenyl) ethyl, 5-carboxymethoxy-2-nitrobenzyl, 5-carboxymethoxy-2-nitrobenzyl)oxy)carbonyl, 4,5-dimethyoxy-2-nitrobenzyl, 4,5-dimethoxy-2-nitrobenzyl)oxy)carbonyl, alpha-carboxy-2-nitrobenzyl, 1-(2-nitropheny)ethyl, 2-nitrobenzyl and Desoxybenzoinyl.

### Claim 29 (depends on 27)

The method of claim 27, wherein the caging group is DMNPE 1-(4,5-dimethyoxy-2-nitrophenyl) ethyl.

### Claim 30 (depends on 27)

The method of claim 27, wherein the wavelength of the light is in a range from 300 nm to 400 nm.

### Claim 31 (depends on 27)

The method of claim 27, wherein the wavelength of the light is 365 nm.

### Claim 32 (depends on 27)

The method of claim 27, wherein the source of the light is a fiber optic device.

### Claim 33 (depends on 27)

The method of claim 27, wherein the source of the light is a laser.

### Claim 34 (depends on 27)

The method of claim 27, wherein the cell is selected from the group consisting of endothelial cells, epithelial cells and blood cells.

### Claim 35 (depends on 27)

The method of claim 27, wherein the cell is selected from the group consisting of lung cells, skin cells, eye cells and lymphocytes.

### Claim 36 (depends on 27)

The method of claim 27, wherein the nucleic acid is administered to the cell in a vector.

### Claim 37 (depends on 27)

The method of claim 27, wherein the nucleic acid is administered to the cell in a virus.

### Claim 38 (depends on 27)

The method of claim 27, wherein the nucleic acid is administered to the cell in a liposome.

### Claim 39 (depends on 27)

The method of claim 27, wherein the cell is in a subject.

### Claim 40 (depends on 27)

The method of claim 27, wherein the nucleic acid is in a pharmaceutically acceptable carrier.

### Claim 41 (depends on 36)

The method of claim 36, wherein the vector is in a pharmaceutically acceptable carrier.

### Claim 42 (depends on 37)

The method of claim 37, wherein the virus is in a pharmaceutically acceptable carrier.

### Claim 43 (depends on 38)

The method of claim 38, wherein the liposome is in a pharmaceutically acceptable carrier.

### Claim 44 (depends on 39)

The method of claim 39, wherein the subject is a human.

### Claim 45 (depends on 27)

The method of claim 27, wherein the nucleic acid comprises a nucleic acid which is antisense to a gene selected from the group consisting of genes encoding gene products that promote cell killing, genes encoding proteins that are involved in inherited disorders, genes encoding gene products that promote wound repair, genes encoding gene products which promote cell-cell adhesion and genes encoding gene products which modulate cellular signals.
